Switch to:
Also traded in: Austria, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.35
HOLX's Cash-to-Debt is ranked lower than
89% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. HOLX: 0.35 )
Ranked among companies with meaningful Cash-to-Debt only.
HOLX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 5.04 Max: No Debt
Current: 0.35
Equity-to-Asset 0.32
HOLX's Equity-to-Asset is ranked lower than
86% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. HOLX: 0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
HOLX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.02  Med: 0.7 Max: 0.88
Current: 0.32
0.02
0.88
Interest Coverage 9.25
HOLX's Interest Coverage is ranked lower than
90% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.06 vs. HOLX: 9.25 )
Ranked among companies with meaningful Interest Coverage only.
HOLX' s Interest Coverage Range Over the Past 10 Years
Min: 0.55  Med: 2.21 Max: 71.1
Current: 9.25
0.55
71.1
Piotroski F-Score: 7
Altman Z-Score: 1.66
Beneish M-Score: -2.42
WACC vs ROIC
5.36%
17.94%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 49.49
HOLX's Operating Margin % is ranked higher than
85% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.86 vs. HOLX: 49.49 )
Ranked among companies with meaningful Operating Margin % only.
HOLX' s Operating Margin % Range Over the Past 10 Years
Min: -123.18  Med: 8.37 Max: 20.93
Current: 49.49
-123.18
20.93
Net Margin % 27.30
HOLX's Net Margin % is ranked higher than
78% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.79 vs. HOLX: 27.30 )
Ranked among companies with meaningful Net Margin % only.
HOLX' s Net Margin % Range Over the Past 10 Years
Min: -135.4  Med: -1.5 Max: 12.81
Current: 27.3
-135.4
12.81
ROE % 35.10
HOLX's ROE % is ranked higher than
80% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. HOLX: 35.10 )
Ranked among companies with meaningful ROE % only.
HOLX' s ROE % Range Over the Past 10 Years
Min: -60.17  Med: -0.73 Max: 15.67
Current: 35.1
-60.17
15.67
ROA % 10.41
HOLX's ROA % is ranked higher than
61% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.23 vs. HOLX: 10.41 )
Ranked among companies with meaningful ROA % only.
HOLX' s ROA % Range Over the Past 10 Years
Min: -32.08  Med: -0.35 Max: 9.84
Current: 10.41
-32.08
9.84
ROC (Joel Greenblatt) % 180.62
HOLX's ROC (Joel Greenblatt) % is ranked higher than
91% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. HOLX: 180.62 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HOLX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -369.68  Med: 25.23 Max: 90.76
Current: 180.62
-369.68
90.76
3-Year Revenue Growth Rate 2.20
HOLX's 3-Year Revenue Growth Rate is ranked lower than
58% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. HOLX: 2.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HOLX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -14.1  Med: 10.3 Max: 41.9
Current: 2.2
-14.1
41.9
GuruFocus has detected 3 Warning Signs with Hologic Inc $HOLX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HOLX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

HOLX Guru Trades in Q2 2016

Robert Olstein 187,000 sh (New)
Leon Cooperman 100,000 sh (New)
Paul Tudor Jones 1,310,684 sh (+2797.05%)
Joel Greenblatt 31,837 sh (+60.84%)
Steven Cohen 715,700 sh (+28.45%)
Vanguard Health Care Fund 7,306,800 sh (+25.92%)
Steven Cohen 55,500 sh (unchged)
RS Investment Management Sold Out
Ray Dalio Sold Out
Jim Simons Sold Out
Kahn Brothers 1,276,984 sh (-3.73%)
Ken Fisher 37,600 sh (-21.04%)
Pioneer Investments 58,312 sh (-48.23%)
» More
Q3 2016

HOLX Guru Trades in Q3 2016

Jim Simons 590,018 sh (New)
George Soros 7,236 sh (New)
Joel Greenblatt 103,903 sh (+226.36%)
Steven Cohen 1,315,600 sh (+83.82%)
Pioneer Investments 85,816 sh (+47.17%)
Robert Olstein 187,000 sh (unchged)
Ken Fisher Sold Out
Leon Cooperman Sold Out
Kahn Brothers 1,234,514 sh (-3.33%)
Vanguard Health Care Fund 6,896,300 sh (-5.62%)
Paul Tudor Jones 1,200,000 sh (-8.44%)
» More
Q4 2016

HOLX Guru Trades in Q4 2016

Jim Simons 1,463,618 sh (+148.06%)
Pioneer Investments 173,374 sh (+102.03%)
George Soros Sold Out
Joel Greenblatt Sold Out
Robert Olstein 184,000 sh (-1.60%)
Kahn Brothers 1,197,404 sh (-3.01%)
Steven Cohen 1,142,100 sh (-13.19%)
Vanguard Health Care Fund 3,538,200 sh (-48.69%)
Paul Tudor Jones 500,000 sh (-58.33%)
» More
Q1 2017

HOLX Guru Trades in Q1 2017

Eaton Vance Worldwide Health Sciences Fund 491,712 sh (New)
Vanguard Health Care Fund 3,538,200 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Jim Simons 1,456,318 sh (-0.50%)
Pioneer Investments 172,100 sh (-0.73%)
Robert Olstein 167,000 sh (-9.24%)
Kahn Brothers 918,399 sh (-23.30%)
» More
» Details

Insider Trades

Latest Guru Trades with HOLX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 334517    SIC: 3844
Compare:OTCPK:OCPNY, NYSE:COO, NYSE:WAT, NYSE:RMD, NAS:XRAY, OTCPK:TRUMF, NYSE:MTD, OTCPK:SAUHY, NYSE:WST, NYSE:STE, OTCPK:CLPBY, OTCPK:GNGBF, NYSE:HRC, NYSE:CMD, NAS:ICUI, OTCPK:ANSLF, NAS:PODD, NYSE:HAE, OTCPK:TOPCF, NYSE:BCR » details
Traded in other countries:HOLX.Austria, HO1.Germany,
Headquarter Location:USA
Hologic Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. It operates in four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health.

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (47% of sales), breast health (37%), surgical (12%), and skeletal health (4%). While the company traditionally focused on breast health, the recent acquisition of Gen-Probe puts a much greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (74%), followed by Europe (12%) and Asia (8%). Hologic is headquartered in Bedford, Massachusetts.

Ratios

vs
industry
vs
history
PE Ratio 15.65
HOLX's PE Ratio is ranked lower than
62% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.48 vs. HOLX: 15.65 )
Ranked among companies with meaningful PE Ratio only.
HOLX' s PE Ratio Range Over the Past 10 Years
Min: 14.89  Med: 54.31 Max: 472.67
Current: 15.65
14.89
472.67
Forward PE Ratio 22.22
HOLX's Forward PE Ratio is ranked higher than
59% of the 78 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.42 vs. HOLX: 22.22 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 15.65
HOLX's PE Ratio without NRI is ranked lower than
61% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.38 vs. HOLX: 15.65 )
Ranked among companies with meaningful PE Ratio without NRI only.
HOLX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 14.89  Med: 53.71 Max: 472.67
Current: 15.65
14.89
472.67
Price-to-Owner-Earnings 8.74
HOLX's Price-to-Owner-Earnings is ranked higher than
72% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.93 vs. HOLX: 8.74 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
HOLX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.31  Med: 24.75 Max: 336.89
Current: 8.74
8.31
336.89
PB Ratio 4.45
HOLX's PB Ratio is ranked lower than
70% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.56 vs. HOLX: 4.45 )
Ranked among companies with meaningful PB Ratio only.
HOLX' s PB Ratio Range Over the Past 10 Years
Min: 0.59  Med: 2.01 Max: 7.98
Current: 4.45
0.59
7.98
PS Ratio 4.25
HOLX's PS Ratio is ranked lower than
59% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. HOLX: 4.25 )
Ranked among companies with meaningful PS Ratio only.
HOLX' s PS Ratio Range Over the Past 10 Years
Min: 1.47  Med: 2.93 Max: 6.01
Current: 4.25
1.47
6.01
Price-to-Free-Cash-Flow 19.94
HOLX's Price-to-Free-Cash-Flow is ranked higher than
78% of the 73 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.88 vs. HOLX: 19.94 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HOLX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.52  Med: 15.31 Max: 2255.38
Current: 19.94
6.52
2255.38
Price-to-Operating-Cash-Flow 17.09
HOLX's Price-to-Operating-Cash-Flow is ranked higher than
63% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.90 vs. HOLX: 17.09 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HOLX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.51  Med: 13.24 Max: 132.61
Current: 17.09
5.51
132.61
EV-to-EBIT 9.89
HOLX's EV-to-EBIT is ranked lower than
52% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.30 vs. HOLX: 9.89 )
Ranked among companies with meaningful EV-to-EBIT only.
HOLX' s EV-to-EBIT Range Over the Past 10 Years
Min: -137.4  Med: 26.3 Max: 153.7
Current: 9.89
-137.4
153.7
EV-to-EBITDA 7.56
HOLX's EV-to-EBITDA is ranked higher than
71% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.15 vs. HOLX: 7.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
HOLX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -344.2  Med: 13.1 Max: 100.6
Current: 7.56
-344.2
100.6
Current Ratio 0.86
HOLX's Current Ratio is ranked lower than
68% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. HOLX: 0.86 )
Ranked among companies with meaningful Current Ratio only.
HOLX' s Current Ratio Range Over the Past 10 Years
Min: 0.86  Med: 2.88 Max: 7.31
Current: 0.86
0.86
7.31
Quick Ratio 0.70
HOLX's Quick Ratio is ranked lower than
52% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. HOLX: 0.70 )
Ranked among companies with meaningful Quick Ratio only.
HOLX' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 2.31 Max: 6.57
Current: 0.7
0.7
6.57
Days Inventory 83.16
HOLX's Days Inventory is ranked higher than
77% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.79 vs. HOLX: 83.16 )
Ranked among companies with meaningful Days Inventory only.
HOLX' s Days Inventory Range Over the Past 10 Years
Min: 65.34  Med: 88.04 Max: 108.2
Current: 83.16
65.34
108.2
Days Sales Outstanding 57.60
HOLX's Days Sales Outstanding is ranked higher than
67% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.76 vs. HOLX: 57.60 )
Ranked among companies with meaningful Days Sales Outstanding only.
HOLX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.15  Med: 60.73 Max: 75.51
Current: 57.6
56.15
75.51
Days Payable 49.67
HOLX's Days Payable is ranked lower than
66% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.53 vs. HOLX: 49.67 )
Ranked among companies with meaningful Days Payable only.
HOLX' s Days Payable Range Over the Past 10 Years
Min: 21.81  Med: 27.28 Max: 45.11
Current: 49.67
21.81
45.11

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.70
HOLX's 3-Year Average Share Buyback Ratio is ranked higher than
69% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.20 vs. HOLX: -0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HOLX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -53.1  Med: -6.1 Max: -0.7
Current: -0.7
-53.1
-0.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.74
HOLX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
62% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.03 vs. HOLX: 1.74 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HOLX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.45  Med: 1.68 Max: 13.86
Current: 1.74
0.45
13.86
Price-to-Median-PS-Value 1.45
HOLX's Price-to-Median-PS-Value is ranked lower than
69% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. HOLX: 1.45 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HOLX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 0.8 Max: 2.58
Current: 1.45
0.15
2.58
Earnings Yield (Greenblatt) % 10.11
HOLX's Earnings Yield (Greenblatt) % is ranked higher than
63% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.18 vs. HOLX: 10.11 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HOLX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.7  Med: 2.9 Max: 10.4
Current: 10.11
0.7
10.4
Forward Rate of Return (Yacktman) % 25.81
HOLX's Forward Rate of Return (Yacktman) % is ranked higher than
84% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. HOLX: 25.81 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
HOLX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.4  Med: 6.9 Max: 72.7
Current: 25.81
0.4
72.7

More Statistics

Revenue (TTM) (Mil) $2,894
EPS (TTM) $ 2.77
Beta0.61
Short Percentage of Float2.79%
52-Week Range $32.64 - 46.05
Shares Outstanding (Mil)280.01

Analyst Estimate

Sep17 Sep18 Sep19
Revenue (Mil $) 2,977 3,193 3,371
EPS ($) 1.96 2.18 2.38
EPS without NRI ($) 1.96 2.18 2.38
EPS Growth Rate
(Future 3Y To 5Y Estimate)
7.53%
Dividends per Share ($)
» More Articles for HOLX

Headlines

Articles On GuruFocus.com
Eaton Vance Worldwide Health Sciences Fund Adds 4 Companies May 17 2017 
Charles J. Dockendorff Elected to Hologic Board of Directors May 16 2017 
Hologic to Webcast Presentations at Upcoming Investor Conferences May 08 2017 
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2017 on Wednesday, May 10, 20 Apr 04 2017 
Hologic Delivers Notice that Holders of 2.00% Convertible Exchange Senior Notes Due 2042 are Eligibl Apr 03 2017 
Robert Olstein's Best Performing Investments Include eBay Aug 14 2016 
Carl Icahn's Stakes with Positive Return Aug 04 2016 
Edward Owens Top 2nd Quarter Investments Aug 03 2016 
Carl Icahn's Largest Trades of the 2nd Quarter Jul 19 2016 
Carl Icahn Continues to Reduce Position in Hologic Apr 07 2016 

More From Other Websites
Post Earnings Coverage as Hologic's Q2 Results Outperformed Expectations May 26 2017
Hologic, Inc. breached its 50 day moving average in a Bullish Manner : HOLX-US : May 26, 2017 May 26 2017
Envision (EVHC) Acquires Gwinnett Emergency Specialists May 23 2017
Halyard Health (HYH) Expands CORGRIP System Product Line May 23 2017
Hologic (HOLX) Poised on Balanced Growth Amid Currency Woes May 23 2017
Integra Lifesciences Hits 52-Week High on Product Launches May 22 2017
Quest Diagnostics Poised on Solid Q1 Results Despite Woes May 22 2017
Intuitive Surgical at 52-Week High: What's Driving the Stock? May 22 2017
Quality Systems (QSII) Beats Q4 Earnings, Issues FY18 View May 22 2017
Medtronic (MDT) RESOLUTE ONYX Meets Primary Study Endpoint May 19 2017
McKesson (MCK) Beats Earnings Estimate in Q4, Revenues Miss May 19 2017
Halyard Health-Sustainable Solutions Ink License Agreement May 19 2017
Hill Rom Impresses with Q2 Results, Strategic Initiatives May 19 2017
Exactech (EXAC) Gets FDA Approval for ExactechGPS Application May 18 2017
Boston Scientific's Symetis Buyout Boosts Structural Heart May 18 2017
Medtronic's MyCareLink Data on Older Patients Found Positive May 18 2017
Halyard Health Announces New Drainage System, Stock Down May 18 2017
Eaton Vance Worldwide Health Sciences Fund Adds 4 Companies May 17 2017
Boston Scientific Hits a 52-Week High on Solid Prospects May 17 2017
Abbott Lab Well Poised on Strong EPD, St. Jude Integration May 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)